Eli Lilly and Company
Tracked across 44 events · 606 articles · First seen Mar 09, 2018 · Last active Jul 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Eli Lilly and Company has launched its cancer drug Tanstrive in India, expanding its market presence and offering a new treatment option for patients with RET-altered cancers. This launch is expected to positively impact the company's revenue and reputation in the Indian market.
Jun 25, 2026 · 7 articles
Regulatory
Impact: Eli Lilly and Company agreed to lower prices for its obesity drug Zepbound and will sell a starter dose for $299 a month, with additional doses up to $449, representing $50 reductions from current direct-to-patient prices. Its sales of Zepbound have tripled this year to over $9 billion.
Nov 06, 2025 · 6 articles
Tech
Impact: Eli Lilly and Company produces donanemab (Kisunla), one of the anti-amyloid drugs whose effectiveness was questioned by the Cochrane review, potentially impacting its sales and stock price.
Apr 16, 2026 · 6 articles
Business
Impact: Eli Lilly and Company is a leading pharmaceutical company with strong balance sheets, enabling it to be a major acquirer in the current M&A wave. It is also facing patent expirations on some of its blockbuster drugs.
May 01, 2026 · 6 articles
Business
Impact: Eli Lilly and Company has partnered with DKSH to expand the distribution and promotion of its pharmaceutical products in China — Hong Kong and China — Macau, ensuring continued patient access to its medicines.
Jul 06, 2026 · 6 articles
Tech
Impact: Eli Lilly and Company>>> produces GLP-1 drugs like Zepbound, Mounjaro, and Trulicity, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
Regulatory
Impact: Eli Lilly and Company is a pharmaceutical company also facing lawsuits for its GLP-1 medications, Tirzepatide and Tirzepatide, which are alleged to have caused NAION. The company is accused of failing to warn consumers about these risks.
May 22, 2026 · 7 articles
Business
Impact: Eli Lilly and Company is a major competitor to Novo Nordisk in the weight-loss and diabetes drug market, with its drug Zepbound gaining market share against Novo Nordisk's Wegovy.
Sep 10, 2025 · 6 articles
Business
Impact: Eli Lilly and Company's drug Tirzepatide has been a strong competitor to Semaglutide in India, prompting Novo Nordisk to cut prices. Eli Lilly and Company has gained significant market share.
Nov 11, 2025 · 6 articles
Business
Impact: Eli Lilly and Company faces increased competition with Novo Nordisk's Wegovy pill launch, potentially impacting its market dominance in weight-loss drugs. Its shares fell following the announcement.
Jan 05, 2026 · 7 articles
Tech
Impact: Eli Lilly and Company produces Tirzepatide and Tirzepatide, which are GLP-1 agonist drugs. The study's findings on rapid weight regain after stopping medication could affect the perceived long-term efficacy and market demand for their products.
Jan 08, 2026 · 6 articles
Tech
Impact: Eli Lilly and Company collaborated on a new study that found a 71% higher risk of cardiovascular events or death in people with obstructive sleep apnea, especially those with obesity. This research could influence the development of new treatments and diagnostics, potentially benefiting Eli Lilly and Company's market position in related therapeutic areas.
Apr 03, 2026 · 6 articles
Domestic
Impact: Eli Lilly and Company rose after the United States — Food and Drug Administration approved its new weight loss pill, Foundayo.
Apr 01, 2026 · 14 articles
Business
Impact: Eli Lilly and Company is a recipient of the 2026 Visionary Growth Leadership Best Practices Recognition, which could positively influence its brand image and investor perception.
Jun 15, 2026 · 6 articles
Domestic
Impact: Eli Lilly and Company, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Business
Impact: Eli Lilly and Company is a competitor in the Indian weight-loss drug market with its product Mounjaro, which has seen greater uptake than Novo Nordisk's Wegovy.
Nov 10, 2025 · 6 articles
Business
Impact: Eli Lilly is partnering with Abridge to streamline care across the health sector.
Jun 24, 2026 · 8 articles
Domestic
Impact: Eli Lilly is an employer involved in the RaiseMe project, contributing to the nonprofit's goal of adapting the workforce to an AI economy.
Jun 25, 2026 · 7 articles
International
Impact: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.
Jun 03, 2026 · 191 articles
Business
Impact: Eli Lilly and Company participated in Myricx Bio's Series A funding round, showing early investor confidence in the company's technology.
Jul 05, 2026 · 21 articles
Domestic
Impact: Eli Lilly and Company saw gains that helped offset drops in other sectors, contributing to the overall positive market performance.
Dec 11, 2025 · 7 articles
Business
Impact: Gavin Barnard previously held senior leadership roles at Eli Lilly and Company, contributing to his extensive biopharma experience.
Apr 16, 2026 · 6 articles
Business
Impact: Eli Lilly and Company developed Kisunla, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
Business
Impact: Eli Lilly and Company is mentioned as having a previous collaboration and out-licensing agreement with AlzeCure Pharma on the Alzstatin platform, providing context for AlzeCure's business model.
Jul 01, 2026 · 6 articles
+ 14 more events
View on Dashboard
100
Eli Lilly and Company launched drug IndiaEli Lilly launches...
100
DKSH entered partnership Eli Lilly and CompanyDKSH, Lilly Partner in Hong Kong
90
Eli Lilly and Company produced GLP-1 drugsGLP-1 Drugs Reduce Cancer Risk
90
Parker Waichman LLP filed lawsuits Eli Lilly and CompanyParker Waichman Sues Novo...
85
Eli Lilly and Company produced drugsParker Waichman Sues Novo...
80
India — Central Drugs Standard Control Organisation granted marketing authorization Eli Lilly and CompanyEli Lilly launches...
50
Abridge partners with Eli Lilly and CompanyNYSE Daily Pre-Market Update
40
Eli Lilly and Company released trial resultsChip Earnings Boost AI Rally
40
CVS Health restore coverage Eli Lilly and CompanyIran attacks Kuwait,...
+ 82 more relationships
View on Dashboard
ERGEN INTELLIGENCE
Track Eli Lilly and Company live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard